Detecting progression in GEP-NETs
A multicenter open-label study to evaluate safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheochromocytomas and paragangliomas (PPGLs)
A Phase Ib dose-finding study assessing safety and activity of [177Lu]Lu-DOTA-TATE in newly diagnosed glioblastoma (GBM) in combination with radiotherapy with or without temozolomide, and in recurrent GBM as a single agent
A phase Ib dose finding study assessing safety and activity of [177Lu]Lu-DOTA-TATE in newly diagnosed ES-SCLC in combination with carboplatin, etoposide, and tislelizumab in induction and with tislelizumab in maintenance treatment phase
A Phase I/IIa, open-label, multicenter study to evaluate the safety, tolerability, whole-body distribution, radiation dosimetry and antitumor activity of [177Lu]Lu-NeoB administered in patients with advanced solid tumors known to overexpress gastrin-releasing peptide receptor (GRPR)
This site may contain information of products which have not been authorized in your country.
Please note that the following content is exclusively addressed to healthcare professionals and its correct interpretation requires specialized training.
Are you a healthcare professional?
Copyright © 2021 Novartis AG. All rights reserved.